Industry leading product available through Twist ecommerce platform

Twist Gene Fragments now available up to 5.0kb in length with the same speed, quality, and affordability as shorter fragments

Turnaround time starting at two business days

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8kb to 5.0kb.

“Leveraging our Express Genes workflow, industry-leading error rate and rapid turnaround times, we continue to push the boundaries of what is possible in DNA synthesis to expand our portfolio of products that enable our customers to quickly and efficiently advance their research,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Our goal is to serve all researchers no matter where they are in their customer journey, whether they are Makers, Buyers or transitioning from Makers to Buyers. With the versatility, speed, high quality, scalability, competitive pricing, and now increased length of Twist Gene Fragments, we can further penetrate the Maker's Market and meet the needs of customers who previously had to stitch together shorter fragments, as well as enable customers working in RNA therapeutic screening applications.”

Twist’s low error rate of 1:7,500 base pairs enables the production of longer fragments that can be easily incorporated into workflows, allowing researchers to select fewer colonies for screening or to use the gene fragments directly in in vitro transcription to make RNA. The increased length of the Gene Fragment gives researchers the ability to further customize and incorporate more elements into the fragment. Turnaround time for all Gene Fragments starts at two business days, regardless of length.

Twist Gene Fragments

Twist Gene Fragments are universally compatible with various downstream cloning methods, allowing for seamless integration into a wide array of applications. They can be utilized in protein engineering, antibody discovery, pathway engineering, functional genomics, diagnostic assays and other fields. Twist Gene Fragments are customizable and have no order limit. Turnaround time for Gene Fragments 0.3-5.0kb starts at two business days.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, our ability to penetrate the maker’s market, the compatibility of this product with downstream cloning methods and integration into a wide array of applications. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808863612/en/